Ignota Labs: Partnerships and Licensing

Partnership and licensing opportunities from Ignota Labs.

 

Partnership Title: SAFEPATH is the AI based technology platform used to turnaround drugs that have failed in clinical trials.

In preclinical and clinical studies, safety assessments typically reveal what went wrong—such as liver failure or cardiac arrest—but fail to explain why these issues occurred or how they might be mitigated.

 

SAFEPATH combines advanced machine learning models with a multimodal data approach to enable a deep understanding of toxicity mechanisms, offering actionable insights to facilitate drug turnaround.

In this white paper, our Cofounder and Chief Data Science Officer Dr. Layla Hosseini-Gerami explains how our innovative platform works.

• Licencing Out
  We offer our products to other companies on an 'out-licensing' basis.

• Research and Development
  We offer co-development opportunities.

• Active Pharmaceutical Ingredients
  - Development Platforms-Small Molecules

• Biopharmaceuticals
  - Biopharmaceuticals-Technology
  - Biopharmaceuticals-Development Platforms

Claim This Profile

This is the Partnership and Licensing section of the company profile page for Ignota Labs on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.